Literature DB >> 28684437

The role and clinical implications of diastolic dysfunction in aortic stenosis.

Polydoros N Kampaktsis1,2, Damianos G Kokkinidis2,3, Shing-Chiu Wong1, Manolis Vavuranakis4, Nikolaos J Skubas5, Richard B Devereux1.   

Abstract

Diastolic dysfunction in aortic stenosis results primarily from left ventricular hypertrophy and myocardial fibrosis due to chronically elevated left ventricular systolic pressure. Currently, diastolic dysfunction does not have an explicit clinical role in management of patients with aortic stenosis. Studies have shown that improvement in diastolic dysfunction follows left ventricular remodelling after aortic valve replacement and that it occurs gradually or incompletely. Retrospective studies suggest that advanced grades of diastolic dysfunction at baseline are associated with increased mortality and adverse events even after aortic valve replacement. Recent studies have also associated myocardial fibrosis, a hallmark of diastolic dysfunction, with worse outcomes. In addition, these results were independent of the degree of aortic stenosis or valve replacement. Indirect evidence of the role of diastolic dysfunction in aortic stenosis also comes from paradoxical low-flow, low-gradient aortic stenosis, where disproportionate left ventricular hypertrophy leads to underfilling of the left ventricle, low-flow state and is associated with worse prognosis. Lastly, a limited number of studies suggest that worse diastolic dysfunction at baseline is detrimental in patients who develop aortic regurgitation after transcatheteraortic valve replacement, due to superimposition of volume overload on a stiff left ventricle. Current major limitations in our understanding of the prognostic role of diastolic dysfunction are the lack of universally accepted classification schemes, its dependence on dynamic loading conditions and the lack of larger prospective studies. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Aortic stenosis; Heart failure; Myocardial disease

Mesh:

Year:  2017        PMID: 28684437     DOI: 10.1136/heartjnl-2017-311506

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  10 in total

1.  Echocardiographic L-wave as a prognostic indicator in transcatheter aortic valve replacement.

Authors:  Ilan Merdler; Eyal Richert; Aviram Hochstadt; Itamar Loewenstein; Samuel Morgan; Tamar Itach; Yan Topilsky; Ariel Finkelstein; Michal Laufer-Perl; Shmuel Banai; Ben Sadeh
Journal:  Int J Cardiovasc Imaging       Date:  2020-06-17       Impact factor: 2.357

2.  Genetic and phenotypic profiling of supranormal ejection fraction reveals decreased survival and underdiagnosed heart failure.

Authors:  Iain S Forrest; Ghislain Rocheleau; Shantanu Bafna; Edgar Argulian; Jagat Narula; Pradeep Natarajan; Ron Do
Journal:  Eur J Heart Fail       Date:  2022-03-12       Impact factor: 17.349

Review 3.  Detection of myocardial fibrosis by speckle-tracking echocardiography: from prediction to clinical applications.

Authors:  Matteo Lisi; Matteo Cameli; Giulia Elena Mandoli; Maria Concetta Pastore; Francesca Maria Righini; Flavio D'Ascenzi; Marta Focardi; Andrea Rubboli; Sergio Mondillo; Michael Y Henein
Journal:  Heart Fail Rev       Date:  2022-01-19       Impact factor: 4.654

4.  Pulmonary Hypertension in Aortic and Mitral Valve Disease.

Authors:  Micha T Maeder; Lukas Weber; Marc Buser; Marc Gerhard; Philipp K Haager; Francesco Maisano; Hans Rickli
Journal:  Front Cardiovasc Med       Date:  2018-05-23

5.  MicroRNA profiles in plasma samples from young metabolically healthy obese patients and miRNA-21 are associated with diastolic dysfunction via TGF-β1/Smad pathway.

Authors:  Pengkang Yang; Xin Dong; Yuyang Zhang
Journal:  J Clin Lab Anal       Date:  2020-02-28       Impact factor: 2.352

6.  NT-proBNP and postoperative heart failure in surgery for aortic stenosis.

Authors:  Huiqi Jiang; Farkas Vánky; Henrik Hultkvist; Jonas Holm; Yanqi Yang; Rolf Svedjeholm
Journal:  Open Heart       Date:  2019-05-22

7.  HFA-PEFF score: prognosis in patients with preserved ejection fraction after transcatheter aortic valve implantation.

Authors:  Hatim Seoudy; Mira von Eberstein; Johanne Frank; Maren Thomann; Thomas Puehler; Georg Lutter; Matthias Lutz; Peter Bramlage; Norbert Frey; Mohammed Saad; Derk Frank
Journal:  ESC Heart Fail       Date:  2022-01-29

8.  Prognostic value of left atrial strain in patients with congenital aortic stenosis.

Authors:  Ferit Onur Mutluer; Daniel J Bowen; Roderick W J van Grootel; Isabella Kardys; Jolien W Roos-Hesselink; Annemien E van den Bosch
Journal:  Eur Heart J Open       Date:  2022-04-06

9.  Inhibition of the cardiac fibroblast-enriched histone methyltransferase Dot1L prevents cardiac fibrosis and cardiac dysfunction.

Authors:  Jie Xu; Jinghuan Wang; Fen Long; Wen Zhong; Haibi Su; Zhenghua Su; Xinhua Liu
Journal:  Cell Biosci       Date:  2022-08-19       Impact factor: 9.584

10.  Frailty in patients undergoing transcatheter aortic valve replacement: from risk scores to frailty-based management.

Authors:  Andreas Tzoumas; Damianos G Kokkinidis; Stefanos Giannopoulos; George Giannakoulas; Leonidas Palaiodimos; Dimitrios V Avgerinos; Polydoros N Kampaktsis; Robert T Faillace
Journal:  J Geriatr Cardiol       Date:  2021-06-28       Impact factor: 3.327

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.